Key clinical point: Use of topical calcineurin inhibitors (TCIs) in patients with atopic dermatitis (AD) does not appear to increase the risk of keratinocyte carcinomas (KCs), basal cell carcinomas (BCCs), and squamous cell carcinomas (SCCs).

Major finding: Compared with patients exposed to topical corticosteroids, the results showed no association between risk of KCs and exposure to TCIs in patients with AD (adjusted hazard ratio, 1.02; 95% confidence interval, 0.93-1.13). The researchers also found no significant differences in risk of BCCs and TCI exposure (aHR, 1.01; 95% CI, 0.90-1.14) and risk of SCCs and TCI exposure (aHR, 0.94; 95% CI, 0.82-1.08), compared with patients exposed to topical corticosteroids.

Study details: A postmarket surveillance study of 93,746 patients with AD taking TCIs, topical corticosteroids, or neither medication between January 2002 and December 2013.

Disclosures: The study was funded by Valeant Pharmaceuticals. Dr. Asgari reported receiving grants from Valeant and Pfizer. The other authors reported no relevant conflicts of interest.